Our portfolio
BioNTech

Cutting-edge tech for cancer, HIV, TB therapeutics

BioNTech focuses on combining groundbreaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and other serious diseases. The foundation works with BioNTech on developing preclinical vaccines and immunotherapy candidates to prevent HIV and TB infection, working toward durable antiretroviral therapy-free remission of HIV disease.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Active
  • Initial investment
    Series C
  • Partnered in
    2019
  • Investment lead
    Chris Chen
  • Headquarters
    Germany
  • Program strategy
    Discovery & Translational Sciences
Portfolio news
BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.